Holen Sie sich die Stockscreener-App
54.39
0.89%
-0.49
Handel nachbörslich:
54.39
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Are MoonLake Immunotherapeutics' (MLTX) Rising Losses a Sign of Strategic Investment or Mounting Pressure? - simplywall.st
MoonLake Immunotherapeutics: Maintaining A Small Holding (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics: Robust Financials and Promising Phase 3 VELA Program Back Strong Buy Rating - AInvest
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position - TipRanks
Does Rising Loss at MoonLake Immunotherapeutics (MLTX) Signal Strategic Investment or Expense Control Challenges? - simplywall.st
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Leerink Partners Maintains Buy Rating on MoonLake Immunotherapeutics with $73 Price Target - AInvest
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66 - 富途牛牛
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results And Provides A Business Update - TradingView
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics's Q2 net loss widens - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics AG - Via Ritzau
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating - TipRanks
Is MoonLake Immunotherapeutics a growth stock or a value stockTremendous wealth creation - Jammu Links News
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Achieve remarkable returns with smart investing - Jammu Links News
What institutional investors are buying MoonLake Immunotherapeutics stockOutstanding capital returns - Jammu Links News
What are MoonLake Immunotherapeutics company’s key revenue driversIdentify breakout stocks before they peak - Jammu Links News
Published on: 2025-08-03 09:53:42 - Jammu Links News
What are analysts’ price targets for MoonLake Immunotherapeutics in the next 12 monthsPre Market Picks With High Returns - Jammu Links News
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment - Insider Monkey
MoonLake Immunotherapeutics Advances with Phase 3 Trials for Immunologic Disease Treatment - AInvest
Pattern recognition hints at MoonLake Immunotherapeutics upsideReal-Time Analysis With Entry Targets In Progress - metal.it
MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 20:29:47 - beatles.ru
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):